文献速递泌尿生殖技术与安全PETMRCT

18F-氟胆碱PET全身MRI在高危前列腺癌分期中的应用

18F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer.
PubMed 文献 · AJR Am J Roentgenol · 2018-01-11

前瞻性研究纳入58例未治疗高危前列腺癌患者,比较常规分期、PET、全身MRI及PET/全身MRI对转移灶的检出,以病理、影像和临床随访为标准。PET检出转移的敏感度显著高于常规影像和全身MRI,PET/全身MRI对正确N/M分期优于常规影像和全身MRI,其分期可能与早期生化失败相关但未达统计学显著。

要点

  • PET检出转移灶敏感度93.5%(72/77),显著高于常规影像63.6%(49/77)和全身MRI 72.7%(56/77)。
  • PET/全身MRI检出全部77处转移灶(100%),较单PET有改善趋势(p=0.059)。
  • PET及PET/全身MRI对正确N/M分期优于常规影像(p=0.002)和全身MRI(p=0.008)。

核心结论

  • 在高危前列腺癌患者中,FCH PET和FCH PET/全身MRI检出的转移灶显著多于常规影像和全身MRI,PET/全身MRI确定的分期可能与早期结局相关。

研究设计与样本

  • 前瞻性研究纳入58例未治疗高危前列腺癌患者,先行常规分期(CT和骨闪烁显像),后行FCH PET/全身MRI(n=10)或FCH PET/CT联合全身MRI(n=48),以病理、影像和临床随访为标准参照,并观察早期临床结局。

关键影像表现/征象

  • FCH PET/全身MRI可显示淋巴结和远处转移灶,用于高危前列腺癌分期。

诊断标准与关键数值

  • PET检出转移的敏感度72/77(93.5%),常规影像49/77(63.6%),全身MRI 56/77(72.7%),PET/全身MRI 77/77(100%)。
  • PET较常规影像敏感度差异p<0.001,PET较全身MRI差异p=0.002,PET/全身MRI较单PET差异p=0.059。
  • PET和PET/全身MRI对正确N/M分期优于常规影像(p=0.002)和全身MRI(p=0.008)。
  • 56例中12例(21.4%)根治性治疗后出现早期生化失败,中位时间7个月(范围1-20个月)。
  • PET/全身MRI分期为M1a或M1b者早期生化失败率4/8(50%),其他患者8/48(16.7%),差异未达统计学显著(p=0.055)。

临床应用与阅片要点

  • 在高危前列腺癌分期中,FCH PET和FCH PET/全身MRI较常规影像和全身MRI检出更多转移灶,PET/全身MRI可能有助于更准确确定N/M分期。

局限性

  • PET/全身MRI较单PET的检出改善仅为趋势(p=0.059),未达统计学显著。
  • PET/全身MRI分期与早期生化失败的相关性未达统计学显著(p=0.055)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study was to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging.

SUBJECTS AND METHODS: A prospective study included 58 patients with untreated high-risk prostate cancer. After conventional staging (CT and bone scintigraphy), patients underwent FCH PET/WBMRI (n = 10) or FCH PET/CT and WBMRI (n = 48). Metastatic sites and disease stage were recorded for each modality (conventional imaging, PET, WBMRI, and PET/WBMRI) and compared with a standard of reference (histopathologic examination, imaging, and clinical follow-up) and early clinical outcomes.

RESULTS: In the detection of metastases, PET had significantly higher sensitivity (72/77 [93.5%]) than conventional imaging (49/77 [63.6%]; p < 0.001) and WBMRI (56/77 [72.7%]; p = 0.002). There was a trend toward improved detection with PET/WBMRI (77/77 [100%]) compared with PET alone (p = 0.059). For correct NM staging, PET and PET/WBMRI performed better than conventional imaging (p = 0.002) and WBMRI (p = 0.008). Twelve of 56 patients (21.4%) had early biochemical failure after radical treatment (median, 7 months; range, 1-20 months). This rate was higher for patients with M1a or M1b disease at PET/WBMRI than for others, but this finding did not reach statistical significance (4/8 [50%] vs 8/48 [16.7%]; p = 0.055).

CONCLUSION: In patients with high-risk prostate cancer, FCH PET and FCH PET/WBMRI depict significantly more metastatic lesions than do conventional imaging and WBMRI. Stage determined with PET/WBMRI may correlate with early outcomes.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Metser U, Berlin A, Halankar J, et al. 18F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer. AJR Am J Roentgenol. 2018. PMID: 29323548. doi:10.2214/AJR.17.18567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。